Sublinox, based on Orexo’s sublingual tablet technology is indicated as a short term treatment of insomnia.
The tablet is a sublingual orally dissolving tablet that is placed under the tongue where it get dissolves and the active substance is absorbed through the mucous membrane.
The drug is expected to be commercialized by the Meda and Valeant joint venture, Meda Valeant Pharma Canada.
Valeant chairman and CEO Michael Pearson said with this approval, they currently anticipate launching this product in the fourth quarter, just one of several pending product launches that their Canadian operations plan on initiating before the end of the year.